Health ❯ Healthcare ❯ Chronic Diseases

Type 2 Diabetes

Management Strategies Treatment Options Cardiovascular Risk Cardiometabolic Health Metabolic Disorders Management and Treatment Obesity Cardiovascular Disease Medication Effects Weight Management

FDA Approves Lilly’s Once-Weekly Basal Insulin Onswik for Adults With Type 2 Diabetes

Clinical trial data showing similar A1c control to daily basal insulin support a U.S. rollout of prefilled KwikPens in coming months.

FDA Expands Mounjaro Label to Include Cardiovascular Risk Reduction

FDA Approves Mounjaro to Lower Heart‑Attack and Stroke Risk in High‑Risk Type 2 Diabetes

CagriSema Combo Lowers Blood Sugar and Drives Bigger Weight Loss Than Semaglutide Alone

FDA Clears Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes

Metformin Lowers Blood Sugar Through Brain Circuit, Mouse Study Finds

FDA Approves Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes

Wave Life Sciences Shares Plunge 30% After Early Obesity Trial Readout

Heart Risks Rebound After GLP-1 Breaks, New Data Show Continuous Use Is Safest

GLP-1 Drugs Tied to Lower Addiction Risk and Harms in Large VA Study

Abbott to Commercialize Novo Nordisk’s Semaglutide in India Under Extensior Brand

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

Pfizer to Commercialize Sciwind’s GLP-1 Ecnoglutide in China Under Exclusive License

Major Lancet Analysis Finds Most Statin Label Side Effects Not Caused by the Drugs

Oral Semaglutide Cuts Serious Heart-Failure Events 22% in Type 2 Diabetes With Heart Failure

Meta-Analysis Finds GLP-1 Drugs Show Little Short-Term Impact on Obesity-Linked Cancer Risk

Real-World Study Finds Semaglutide and Tirzepatide Cut Cardiovascular Risk in Type 2 Diabetes

Metformin Blunts Exercise Benefits in Rutgers Randomized Trial

India Clears Ozempic for Type 2 Diabetes as Novo Nordisk Prepares Launch

EMA Approves Cardiovascular Indication for Novo Nordisk’s Rybelsus